A CRISPR-edited allogeneic anti-CD19 CAR-T cell therapy with a PD-1 knockout (CB-010) in patients with relapsed/refractory B cell non-Hodgkin lymphoma (r/r B-NHL): Updated phase 1 results from the ANTLER trial.
Boyu Hu(University of Utah), Susan O’Brien(University of California, Irvine), Benjamin Thompson(University of Waterloo), Elizabeth Brém(UC Irvine Health), Enrique Zudaire(Centro de Investigación del Cáncer), Mohamad Cherry(University of Oklahoma Health Sciences Center), Loretta J. Nastoupil(The University of Texas MD Anderson Cancer Center), James Essell(Oncology Hematology Care), Socorro Portella(Caribou Biosciences (United States)), Abraham S. Kanate(HonorHealth), Daniel A. Ermann(University of Utah), Lauren Pinter‐Brown(University of California, Irvine), Syed S. H. Rizvi(Cornell University), Kenneth Micklethwaite(Westmead Hospital), Umar Farooq(Wake Forest University), Houston Holmes(Texas Oncology), Ashley Hammad(Caribou Biosciences (United States)), Muhammad Husnain(University of Arizona), Ayad Hamdan(University of California San Diego), Mehdi Hamadani(Medical College of Wisconsin)
Cited by 19
Related Papers
Axicabtagene Ciloleucel CAR T-Cell Therapy in Refractory Large B-Cell Lymphoma
|New England Journal of Medicine|2017|6k
Management of Immune-Related Adverse Events in Patients Treated With Immune Checkpoint Inhibitor Therapy: American Society of Clinical Oncology Clinical Practice Guideline
|Journal of Clinical Oncology|2018|3.7k
Long-term safety and activity of axicabtagene ciloleucel in refractory large B-cell lymphoma (ZUMA-1): a single-arm, multicentre, phase 1–2 trial
|The Lancet Oncology|2018|2.3k
Targeting BTK with Ibrutinib in Relapsed Chronic Lymphocytic Leukemia
|New England Journal of Medicine|2013|2.2k
KTE-X19 CAR T-Cell Therapy in Relapsed or Refractory Mantle-Cell Lymphoma
|New England Journal of Medicine|2020|1.9k